Belatacept Conversion Trial in Renal Transplantation Revised Protocol 05 incorporating Protocol Amendment 08 + Pharmacogenetics Blood Sample Amendment 01 (version 4.0 dated 08-Aug-06)

Trial Profile

Belatacept Conversion Trial in Renal Transplantation Revised Protocol 05 incorporating Protocol Amendment 08 + Pharmacogenetics Blood Sample Amendment 01 (version 4.0 dated 08-Aug-06)

Completed
Phase of Trial: Phase II

Latest Information Update: 01 May 2017

At a glance

  • Drugs Belatacept (Primary) ; Ciclosporin; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 11 Sep 2013 Results at 3 years presented at the 16th Congress of the European Society for Organ Transplantation.
    • 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Jun 2013 Planned end date changed from 1 May 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top